Printer Friendly Version 

Investor Relations Home

Webcast ImageWebcast
Nomura Biotechnology Conference (Live)
11/06/14 at 12:00 p.m. ET
Nomura Biotechnology Conference
Thursday, November 6, 2014  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
ISIS (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$45.00
Change (%) Stock is Up 2.63 (6.21%)
Volume2,687,535
Data as of 10/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
2013 Interactive Annual Report

Recent Press ReleasesMore >>
DateTitle 
10/10/14Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy
Phase 3 ENDEAR study in infants with SMA enrolling; on track to initiate Phase 3 study in children with SMA later this year Isis to host a webcast at 11:30 a.m. EDT on Friday, October 10 CARLSBAD, Calif., Oct. 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMNRx in infants and children with spinal muscular atrophy (SMA) at the 19th International World Muscle Society (WMS) Congress in Ber... 
Printer Friendly Version
10/09/14Isis Pharmaceuticals Earns $18 Million From GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., Oct. 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned an $18 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  "ISIS-TTRRx is the most advanced drug in our collaboration with GSK, and aside from KYNAMRO, it is also the furthest advanced in our late-stage clinical pipeline.  We have patients who have... 
Printer Friendly Version
10/02/14Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress
CARLSBAD, Calif., Oct. 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Webcast and conference call to provide an update on the ongoing open-label Phase 2 clinical studies of ISIS-SMNRx in infants and children with spinal muscular atrophy (SMA), which will be presented on the morning (CEST) of Friday, October 10 at the 19th International World Muscle Society in Berlin, Germany When:    ... 
Printer Friendly Version
10/01/14Isis Pharmaceuticals Earns $1.5 Million From GSK for the Advancement of ISIS-GSK4 Rx
CARLSBAD, Calif., Oct. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1.5 million milestone payment from GSK related to the advancement of the program to develop ISIS-GSK4Rx to treat an undisclosed ocular disease. "Our collaboration with GSK has been very productive resulting in four drugs in development," said B. Lynne Parshall, chief operating officer at Isis.  "We look forward to advancing ISIS-GSK4Rx into clinical development and... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
11/06/14
Nomura Biotechnology Conference
LocationBoston, MA
11/18/14
Stifel Healthcare Conference
LocationNew York, NY US
11/20/14
Goldman Sachs US Emerging / SMID Cap Growth Conference
LocationNew York, NY
Primary IR Contact
D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
Phone: 760-603-2331

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.

Subscribe

Receive Isis alerts in your email.

Sign Up